Acarbose attenuates basal and postprandial insulin concentrations but fails to lower blood pressure in the spontaneously hypertensive rat

Arthur L Swislocki, Claude K. Lardinois, Gale Hansen Starich

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Patients with essential hypertension and the spontaneously hypertensive rat (SHR) are insulin-resistant and hyperinsulinemic. These findings suggest the possibility that insulin resistance and hyperinsulinemia may play a pivotal role in blood pressure regulation. Acarbose, an oral antihyperglycemic drug, decreases hyperinsulinemia and hyperglycemia. The purpose of this study was to assess the influence of acarbose on basal and postprandial insulin and glucose levels and whether changes in beta-cell function result in a change in blood pressure measurements. Methods: SHRs were fed custom diets ad libitum, six with and six without acarbose (40mg/100g of chow). Fasting and postprandial glucose and insulin levels were analyzed following glucose administration (1.75 g/kg body weight). Blood pressure was determined by the tail cuff method. Results: Fasting glucose values were similar, but fasting insulin levels declined 23% in the acarbose treated group (P < .05). Postprandial glucose and insulin levels decreased 18% and 20%, respectively (P < .01), in the acarbose group vs the control animals. Despite the decrease in fasting and postprandial insulin concentrations, systolic, mean, and calculated diastolic blood pressures were insignificantly different in the acarbose group after six weeks of treatment compared to control animals. Conclusion: Acarbose decreases fasting insulin levels and postprandial glucose and insulin levels without effectively lowering blood pressure in the SHR. The ability of acarbose to attenuate the hyperinsulinemic state in the SHR without effectively lowering blood pressure suggests that factors other than serum insulin concentration are important in the modulation of blood pressure.

Original languageEnglish (US)
Pages (from-to)297-304
Number of pages8
JournalMetabolic Syndrome and Related Disorders
Volume5
Issue number4
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Acarbose
Inbred SHR Rats
Insulin
Blood Pressure
Fasting
Glucose
Hyperinsulinism
Aptitude
Hypoglycemic Agents
Hyperglycemia
Insulin Resistance
Tail
Body Weight
Diet

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Acarbose attenuates basal and postprandial insulin concentrations but fails to lower blood pressure in the spontaneously hypertensive rat. / Swislocki, Arthur L; Lardinois, Claude K.; Starich, Gale Hansen.

In: Metabolic Syndrome and Related Disorders, Vol. 5, No. 4, 01.12.2007, p. 297-304.

Research output: Contribution to journalArticle

@article{641c4d25d9614b58a12d15cc981c6ff5,
title = "Acarbose attenuates basal and postprandial insulin concentrations but fails to lower blood pressure in the spontaneously hypertensive rat",
abstract = "Background: Patients with essential hypertension and the spontaneously hypertensive rat (SHR) are insulin-resistant and hyperinsulinemic. These findings suggest the possibility that insulin resistance and hyperinsulinemia may play a pivotal role in blood pressure regulation. Acarbose, an oral antihyperglycemic drug, decreases hyperinsulinemia and hyperglycemia. The purpose of this study was to assess the influence of acarbose on basal and postprandial insulin and glucose levels and whether changes in beta-cell function result in a change in blood pressure measurements. Methods: SHRs were fed custom diets ad libitum, six with and six without acarbose (40mg/100g of chow). Fasting and postprandial glucose and insulin levels were analyzed following glucose administration (1.75 g/kg body weight). Blood pressure was determined by the tail cuff method. Results: Fasting glucose values were similar, but fasting insulin levels declined 23{\%} in the acarbose treated group (P < .05). Postprandial glucose and insulin levels decreased 18{\%} and 20{\%}, respectively (P < .01), in the acarbose group vs the control animals. Despite the decrease in fasting and postprandial insulin concentrations, systolic, mean, and calculated diastolic blood pressures were insignificantly different in the acarbose group after six weeks of treatment compared to control animals. Conclusion: Acarbose decreases fasting insulin levels and postprandial glucose and insulin levels without effectively lowering blood pressure in the SHR. The ability of acarbose to attenuate the hyperinsulinemic state in the SHR without effectively lowering blood pressure suggests that factors other than serum insulin concentration are important in the modulation of blood pressure.",
author = "Swislocki, {Arthur L} and Lardinois, {Claude K.} and Starich, {Gale Hansen}",
year = "2007",
month = "12",
day = "1",
doi = "10.1089/met.2007.0004",
language = "English (US)",
volume = "5",
pages = "297--304",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Acarbose attenuates basal and postprandial insulin concentrations but fails to lower blood pressure in the spontaneously hypertensive rat

AU - Swislocki, Arthur L

AU - Lardinois, Claude K.

AU - Starich, Gale Hansen

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Background: Patients with essential hypertension and the spontaneously hypertensive rat (SHR) are insulin-resistant and hyperinsulinemic. These findings suggest the possibility that insulin resistance and hyperinsulinemia may play a pivotal role in blood pressure regulation. Acarbose, an oral antihyperglycemic drug, decreases hyperinsulinemia and hyperglycemia. The purpose of this study was to assess the influence of acarbose on basal and postprandial insulin and glucose levels and whether changes in beta-cell function result in a change in blood pressure measurements. Methods: SHRs were fed custom diets ad libitum, six with and six without acarbose (40mg/100g of chow). Fasting and postprandial glucose and insulin levels were analyzed following glucose administration (1.75 g/kg body weight). Blood pressure was determined by the tail cuff method. Results: Fasting glucose values were similar, but fasting insulin levels declined 23% in the acarbose treated group (P < .05). Postprandial glucose and insulin levels decreased 18% and 20%, respectively (P < .01), in the acarbose group vs the control animals. Despite the decrease in fasting and postprandial insulin concentrations, systolic, mean, and calculated diastolic blood pressures were insignificantly different in the acarbose group after six weeks of treatment compared to control animals. Conclusion: Acarbose decreases fasting insulin levels and postprandial glucose and insulin levels without effectively lowering blood pressure in the SHR. The ability of acarbose to attenuate the hyperinsulinemic state in the SHR without effectively lowering blood pressure suggests that factors other than serum insulin concentration are important in the modulation of blood pressure.

AB - Background: Patients with essential hypertension and the spontaneously hypertensive rat (SHR) are insulin-resistant and hyperinsulinemic. These findings suggest the possibility that insulin resistance and hyperinsulinemia may play a pivotal role in blood pressure regulation. Acarbose, an oral antihyperglycemic drug, decreases hyperinsulinemia and hyperglycemia. The purpose of this study was to assess the influence of acarbose on basal and postprandial insulin and glucose levels and whether changes in beta-cell function result in a change in blood pressure measurements. Methods: SHRs were fed custom diets ad libitum, six with and six without acarbose (40mg/100g of chow). Fasting and postprandial glucose and insulin levels were analyzed following glucose administration (1.75 g/kg body weight). Blood pressure was determined by the tail cuff method. Results: Fasting glucose values were similar, but fasting insulin levels declined 23% in the acarbose treated group (P < .05). Postprandial glucose and insulin levels decreased 18% and 20%, respectively (P < .01), in the acarbose group vs the control animals. Despite the decrease in fasting and postprandial insulin concentrations, systolic, mean, and calculated diastolic blood pressures were insignificantly different in the acarbose group after six weeks of treatment compared to control animals. Conclusion: Acarbose decreases fasting insulin levels and postprandial glucose and insulin levels without effectively lowering blood pressure in the SHR. The ability of acarbose to attenuate the hyperinsulinemic state in the SHR without effectively lowering blood pressure suggests that factors other than serum insulin concentration are important in the modulation of blood pressure.

UR - http://www.scopus.com/inward/record.url?scp=36749019629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749019629&partnerID=8YFLogxK

U2 - 10.1089/met.2007.0004

DO - 10.1089/met.2007.0004

M3 - Article

C2 - 18370799

AN - SCOPUS:36749019629

VL - 5

SP - 297

EP - 304

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 4

ER -